Dominic Hovsepian, MD
Neurology · Palo Alto, CANPI 1154749588
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (58.0%), food and beverage and education — rather than concentrated in one kind of arrangement. SK Life Science, Inc. accounts for 63.0% of it on its own, with 51 other manufacturers making up the rest. Reporting peaked in 2022 at $12,415 and has fallen 91.0% since, to $1,119 in 2025. Among neurology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 640 payments — averaging $50.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$20K
- AbbVie$1K
- Teva Pharmaceuticals USA, Inc.$1K
- UCB, Inc.$841
- Neurocrine Biosciences, Inc.$806
- Biogen$499
- plus $7K from 46 others
What the payments were for
- Speaking & faculty fees$18,88658%
- Food & beverage$13,46041%
- Education$1891%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XCOPRI$14,388
- Cenobamate$4,825
- Leqembi$125
How this compares
$32,534 in reported general payments places this provider in the 90th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 90 | $2,302 |
| Carbamazepine ErCarbamazepine | 12 | $1,987 |
| Memantine Hcl | 80 | $1,799 |
| Oxcarbazepine | 18 | $1,538 |
| Levetiracetam | 54 | $1,536 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 64 | $1,499 |
| Donepezil Hcl | 107 | $1,220 |
| Divalproex Sodium | 13 | $1,032 |
| Lacosamide | 12 | $816 |
| Propranolol Hcl | 11 | $799 |
| Baclofen | 21 | $702 |
| Lamotrigine | 25 | $664 |
| Levetiracetam ErLevetiracetam | 15 | $449 |
| Escitalopram Oxalate | 31 | $449 |
| Citalopram HbrCitalopram Hydrobromide | 17 | $447 |
Paid to pharmacies, not to this prescriber.
Other neurology in Palo Alto
- Lawrence SteinmanPalo Alto$228K
- Andrew BlumenfeldCarlsbad$4.9M
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
- Jack SchimCarlsbad$1.7M
- Parshaw DorrizMission Viejo$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.